Diadema Partners LP Arvinas, Inc. Transaction History
Diadema Partners LP
- $233 Billion
- Q4 2024
A detailed history of Diadema Partners LP transactions in Arvinas, Inc. stock. As of the latest transaction made, Diadema Partners LP holds 2,300 shares of ARVN stock, worth $40,871. This represents 0.02% of its overall portfolio holdings.
Number of Shares
2,300Holding current value
$40,871% of portfolio
0.02%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding ARVN
# of Institutions
224Shares Held
70.9MCall Options Held
1.52MPut Options Held
346K-
Vanguard Group Inc Valley Forge, PA7.06MShares$126 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.73MShares$120 Million6.03% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$111 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.1MShares$72.9 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY3.33MShares$59.3 Million1.04% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $945M
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...